logo
logo

Empowering Targeted Cancer Drug Discovery With Ai And Novel Disease Models, Signet Therapeutics Raises ~$10 Million In Seed-2 Round

Oct 29, 2021•over 3 years ago

Amount Raised

$10 Million

Round Type

seed

Boston

Description

Signet Therapeutics, a biopharmaceutical startup focusing on developing innovative targeted cancer drugs using novel disease models, recently announced it has completed seed-2 round of approximately 10 million US dollars.

Company Information

Company

Signet Therapeutics

Location

Boston, Massachusetts, United States

About

Signet Therapeutics is developing new medicines to meet the unmet medical need for the cancer patients, especially those insensitive to chemotherapy and radiotherapy. By strategically collaborating with XtalPi, Signet brings together the expertise of an AI-powered drug discovery platform and unique novel disease models to discover and optimize promising new candidates for novel targeted cancer drugs. By taking these advantages, we hope to revolutionize traditional drug discovery for small molecules.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech